PHAT
HEALTHCAREPhathom Pharmaceuticals Inc
$12.67+0.07 (+0.60%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving PHAT Today?
No stock-specific AI insight has been generated for PHAT yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$2.33$18.31
$12.67
Fundamentals
Market Cap$1.0B
P/E Ratio—
EPS$-2.09
Dividend Yield—
Dividend / Share—
ROE-34.9%
Profit Margin-0.8%
Debt / Equity—
Trading
Volume909K
Avg Volume (10D)—
Shares Outstanding79.8M
PHAT News
20 articles- Phathom Pharmaceuticals (PHAT) Is Up 11.0% After Narrowing Q1 Loss And Reaffirming 2026 Profitability TimelineYahoo Finance·May 5, 2026
- How The Phathom Pharmaceuticals (PHAT) Narrative Is Shifting Around Profitability And Exclusivity RisksYahoo Finance·May 3, 2026
- Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at DDW 2026 Annual MeetingGlobeNewswire Inc.·May 1, 2026
- Phathom Pharmaceuticals Q1 Earnings Call HighlightsMarketbeat·May 1, 2026
- Phathom Pharmaceuticals, Inc. Q1 2026 Earnings Call SummaryMoby·May 1, 2026
- Phathom (PHAT) Q1 2026 Earnings TranscriptMotley Fool·Apr 30, 2026
- Phathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Tops Revenue EstimatesYahoo Finance·Apr 30, 2026
- Phathom Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business UpdateYahoo Finance·Apr 30, 2026
- Phathom Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, April 30, 2026Yahoo Finance·Apr 20, 2026
- Assessing Phathom Pharmaceuticals (PHAT) Valuation After Strong One Year Shareholder ReturnYahoo Finance·Apr 17, 2026
- Eosinophilic Esophagitis Market in the US to Grow at 13.2% CAGR During the Forecast Period (2026–2036) Owing to the Emergence of Drug Classes Such as TSLP Inhibitors, Glucocorticoid Receptor Agonists, and Immunomodulators | DelveInsightGlobeNewswire Inc.·Apr 13, 2026
- Phathom Pharmaceuticals to Participate in Upcoming Investor ConferencesYahoo Finance·Apr 6, 2026
- Phathom Pharmaceuticals Upgraded by Barclays to Overweight With $18 Target247 Wall St·Mar 27, 2026
- Ocugen Falls as Gene Therapy for Eye Disease Lags in Phase II StudyYahoo Finance·Mar 25, 2026
- ImmunityBio Rises on China Nod to Bladder Cancer Combo TherapyYahoo Finance·Mar 24, 2026
- Puma Biotechnology Stock Declines More Than 9% in a Month: Here's WhyYahoo Finance·Mar 18, 2026
- Mirum Completes Enrollment in Late-Stage EXPAND Study of LivmarliYahoo Finance·Mar 17, 2026
- COGT Rise as FDA Accepts Bezuclastinib NDA in Non-Advanced SMYahoo Finance·Mar 17, 2026
- Mineralys Stock Rises as FDA Accepts NDA for Hypertension DrugYahoo Finance·Mar 11, 2026
- Guggenheim Raises PT on Phathom Pharmaceuticals (PHAT) to $25 From $20, Here’s WhyYahoo Finance·Mar 1, 2026
All 20 articles loaded
Price Data
Open$12.77
Previous Close$12.60
Day High$12.90
Day Low$12.35
52 Week High$18.31
52 Week Low$2.33
52-Week Range
$2.33$18.31
$12.67
Fundamentals
Market Cap$1.0B
P/E Ratio—
EPS$-2.09
Dividend Yield—
Dividend / Share—
ROE-34.9%
Profit Margin-0.8%
Debt / Equity—
Trading
Volume909K
Avg Volume (10D)—
Shares Outstanding79.8M
About Phathom Pharmaceuticals Inc
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company is headquartered in Florham Park, New Jersey.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—